US-FDA inspected Aarti Pharmalabs' Unit-IV at Tarapur, Maharashtra, concluding on 27th March 2026.
Inspection concluded with issuance of Form 483 carrying one procedural observation.
Company will submit corrective and preventive actions to US-FDA within the stipulated period.